Investigator | # patients | Follow up (months) | Dosage (ug/week) | Mean dosage (ug/week) | Hazard ratio | 95% CI |
---|---|---|---|---|---|---|
Calcitrol | ||||||
Naves-Diaz et al. | 1304 | 54 | <1.75 | 1.05 | 0.46 | 0.37–0.53 |
Naves-Diaz et al. | 1053 | 54 | 1.75-3.5 | 2.38 | 0.58 | 0.49–0.70 |
Naves-Diaz et al. | 432 | 54 | 3.5-7.0 | 4.69 | 0.64 | 0.50–0.83 |
Naves-Diaz et al. | 184 | 54 | >7.0 | 11.83 | 0.83 | 0.58–1.19 |
Paricalcitol | ||||||
Kalantar-Zadeh et al. | 5288 | 24 | 1.0-5.0 | NA | 0.53 | 0.50–0.57 |
Kalantar-Zadeh et al. | 11965 | 24 | 5.0-10.0 | NA | 0.54 | 0.51–0.57 |
Kalantar-Zadeh et al. | 8326 | 24 | 10.0-15.0 | NA | 0.54 | 0.51–0.57 |
Kalantar-Zadeh et al. | 11816 | 24 | >15.0 | NA | 0.73 | 0.69–0.77 |
Shinaberger et al. | 9575 | 30 | 1.7-20.1 | 10.9 | 0.93 | 0.89–0.97 |
Shinaberger et al. | 8277 | 30 | 4.6-25.8 | 15.2 | 0.88 | 0.84–0.94 |
Shinaberger et al. | 5875 | 30 | 6.4-30.8 | 18.6 | 0.88 | 0.84–0.93 |